Tumor cell derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8+ T cell activation

17Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The activation and expansion of T cells that recognize cancer cells is an essential aspect to antitumor immunity. Tumors may escape destruction by the immune system through ectopic expression of inhibitory immune ligands typically exemplified by the PD-L1/PD-1 pathway. Here, we reveal another facet of tumor evasion from T cell surveillance. By secretome profiling of necrotic tumor cells, we identified an oncometabolite spermidine as a unique inhibitor of T cell receptor (TCR) signaling. Mechanistically, spermidine causes the downregulation of the plasma membrane cholesterol levels, resulting in the suppression of TCR clustering. Using syngeneic mouse models, we show that spermidine is abundantly detected in the tumor immune microenvironment (TIME) and that administration of the polyamine synthesis inhibitor effectively enhanced CD8+ T cell dependent antitumor responses. Further, the combination of the polyamine synthesis inhibitor with anti-PD-1 immune checkpoint antibody resulted in a much stronger antitumor immune response. This study reveals an aspect of immunosuppressive TIME, wherein spermidine functions as a metabolic T cell checkpoint that may offer a unique approach for promoting tumor immunotherapy.

Cite

CITATION STYLE

APA

Hibino, S., Eto, S., Hangai, S., Endo, K., Ashitani, S., Sugaya, M., … Yanai, H. (2023). Tumor cell derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8+ T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 120(24). https://doi.org/10.1073/pnas.2305245120

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free